Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.

Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.

One company to watch right now is Catalyst Pharmaceuticals (CPRX). CPRX is currently sporting a Zacks Rank #1 (Strong Buy) and an A for Value.

CPRX is also sporting a PEG ratio of 0.72. This figure is similar to the commonly-used P/E ratio, with the PEG ratio also factoring in a company's expected earnings growth rate. CPRX's PEG compares to its industry's average PEG of 1.64. Within the past year, CPRX's PEG has been as high as 3.40 and as low as 0.63, with a median of 1.06.

Finally, we should also recognize that CPRX has a P/CF ratio of 10.23. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 13.81. Within the past 12 months, CPRX's P/CF has been as high as 25.41 and as low as 10.16, with a median of 13.48.

Value investors will likely look at more than just these metrics, but the above data helps show that Catalyst Pharmaceuticals is likely undervalued currently. And when considering the strength of its earnings outlook, CPRX sticks out as one of the market's strongest value stocks.

#1 Semiconductor Stock to Buy (Not NVDA)

The incredible demand for data is fueling the market's next digital gold rush. As data centers continue to be built and constantly upgraded, the companies that provide the hardware for these behemoths will become the NVIDIAs of tomorrow.

One under-the-radar chipmaker is uniquely positioned to take advantage of the next growth stage of this market. It specializes in semiconductor products that titans like NVIDIA don't build. It's just beginning to enter the spotlight, which is exactly where you want to be.

See This Stock Now for Free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research